menu search

COPHF / Creso Pharma's psychedelics subsidiary proceeds to stability testing ahead of clinical trial

Creso Pharma's psychedelics subsidiary proceeds to stability testing ahead of clinical trial
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics company Halucenex Life Sciences Inc has started stability testing initiatives for its Good Manufacturing Practice (GMP) grade psilocybin. This marks a critical component for the company's planned phase II clinical trial and future drug development initiatives, which have been buoyed by a recently released report from the Therapeutics Goods Administration (TGA). Read More
Posted: Oct 6 2021, 00:32
Author Name: Proactive Investors
Views: 110876

COPHF News  

Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

By Proactive Investors
July 18, 2022

Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) (Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF), Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)) subsidiary Halucenex Life more_horizontal

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li more_horizontal

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li more_horizontal

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li more_horizontal

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color more_horizontal

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color more_horizontal

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color more_horizontal

Creso Pharma pushes into US CBD market with revenue-generating acquisition

By Proactive Investors
February 2, 2022

Creso Pharma pushes into US CBD market with revenue-generating acquisition

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has entered the US CBD market. The company has executed a Membership Interest Purchase Agreement to acquire Co more_horizontal


Search within

Pages Search Results: